Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

被引：20

作者：

Zwaginga, Jaap J. ^{[1
,2
]}

van der Holt, Bronno ^{[3
]}

te Boekhorst, Peter A. ^{[5
]}

Biemond, Bart J. ^{[4
]}

Levin, Mark-David ^{[6
]}

van der Griend, Rene ^{[9
]}

Brand, Anneke ^{[1
,2
]}

Zweegman, Sonja ^{[8
]}

Pruijt, Hans F. M. ^{[10
]}

Novotny, Vera M. J. ^{[13
]}

Vreugdenhil, Art ^{[7
]}

de Groot, Marco R. ^{[14
]}

de Weerdt, Okke ^{[11
,21
]}

van Pampus, Elisabeth C. M. ^{[12
]}

van Maanen-Lamme, Tanja M. ^{[15
]}

Wittebol, Shulamiet ^{[16
]}

Schipperus, Martin R. ^{[17
]}

Silbermann, Matthijs H. ^{[18
]}

Huijgens, Peter C. ^{[8
]}

Luten, Marleen ^{[3
]}

Hollestein, Rene ^{[3
]}

Brakenhoff, Jan A. C. ^{[19
]}

Schrama, Jolanda G. ^{[20
]}

Valster, Fransje A. A. ^{[21
]}

Velders, Gerjo A. ^{[22
]}

Koene, Harry R. ^{[11
,21
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RA Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Sanquin, Jon J van Rood Ctr Clin Transfus Res, NL-2300 RA Leiden, Netherlands

[3] Erasmus MC, Inst Canc, Clin Trial Ctr, HOVON Data Ctr, Rotterdam, Netherlands

[4] Acad Med Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[5] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

[6] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[7] Maxima Med Ctr, Dept Internal Med, Veldhoven, Netherlands

[8] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

[9] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands

[10] Jeroen Bosch Hosp, Dept Internal Med, Den Bosch, Netherlands

[11] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[12] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6525 ED Nijmegen, Netherlands

[13] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands

[14] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands

[15] Westfriesgasthuis, Dept Internal Med, Hoorn, Netherlands

[16] Meander Hosp, Dept Internal Med, Amersfoort, Netherlands

[17] HagaZiekenhuis, Dept Internal Med, The Hague, Netherlands

[18] Tergooiziekenhuizen, Dept Internal Med, Blaricum, Netherlands

[19] Waterland Hosp, Purmerend, Netherlands

[20] Spaarne Hosp, Dept Internal Med, Hoofddorp, Netherlands

[21] Lievensberg Hosp, Dept Internal Med, Bergen Op Zoom, Netherlands

[22] Gelderse Vallei Hosp, Dept Internal Med, Ede, Netherlands

来源：

HAEMATOLOGICA | 2015年 / 100卷 / 03期

关键词：

immune thrombocytopenia; rituximab; splenectomy delaying; early response; open label phase II; ADULT PATIENTS; PURPURA; SPLENECTOMY; THERAPY; EFFICACY; SAFETY; CHILDREN;

D O I：

10.3324/haematol.2014.110213

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E90 / E92

页数：3

共 50 条

[31] Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial [J].

Leiping Wang ;

Jun Cao ;

Chunlei Li ;

Xiaodong Wang ;

Yannan Zhao ;

Ting Li ;

Yiqun Du ;

Zhonghua Tao ;

Wenxia Peng ;

Biyun Wang ;

Jian Zhang ;

Sheng Zhang ;

Zhonghua Wang ;

Xichun Hu .

Investigational New Drugs, 2022, 40 :330-339

[32] Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial [J].

Koonrungsesomboon, Nut ;

Ngamphaiboon, Nuttapong ;

Townamchai, Natavudh ;

Teeyakasem, Pimpisa ;

Charoentum, Chaiyut ;

Charoenkwan, Pimlak ;

Natesirinilkul, Rungrote ;

Sathitsamitphong, Lalita ;

Ativitavas, Touch ;

Chaiyawat, Parunya ;

Klangjorhor, Jeerawan ;

Hongeng, Suradej ;

Pruksakorn, Dumnoensun .

BMC CANCER, 2020, 20 (01)

[33] Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study [J].

Alberer, Martin ;

Burchard, Gerd ;

Jelinek, Tomas ;

Reisinger, Emil ;

Beran, Jiri ;

Meyer, Seetha ;

Forleo-Neto, Eduardo ;

Gniel, Dieter ;

Dagnew, Alemnew F. ;

Arora, Ashwani Kumar .

TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2014, 12 (05) :485-493

[34] An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial [J].

Chaker, A. M. ;

Al-Kadah, B. ;

Luther, U. ;

Neumann, U. ;

Wagenmann, M. .

CLINICAL AND TRANSLATIONAL ALLERGY, 2016, 6

[35] A Multi-Center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency [J].

Santamaria, Manuel ;

Neth, Olaf ;

Douglass, Jo A. ;

Krivan, Gergely ;

Kobbe, Robin ;

Bernatowska, Ewa ;

Grigoriadou, Sofia ;

Bethune, Claire ;

Chandra, Anita ;

Horneff, Gerd ;

Borte, Michael ;

Sonnenschein, Anja ;

Kralickova, Pavlina ;

Ramon, Silvia Sanchez ;

Langguth, Daman ;

Gonzalez-Granado, Luis Ignacio ;

Alsina, Laia ;

Querolt, Montse ;

Griffin, Rhonda ;

Hames, Carrie ;

Mondou, Elsa ;

Price, Jeffrey ;

Sanz, Ana ;

Lin, Jiang .

JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (03) :500-511

[36] Randomized, controlled, multi-center phase II study of postoperative enoxaparin treatment for venous thromboembolism prophylaxis in patients undergoing surgery for hepatobiliary-pancreatic malignancies [J].

Shinke, Go ;

Takeda, Yutaka ;

Ohmura, Yoshiaki ;

Kobayashi, Shogo ;

Wada, Hiroshi ;

Morimoto, Osakuni ;

Tomokuni, Akira ;

Shimizu, Junzo ;

Asaoka, Tadafumi ;

Tanemura, Masahiro ;

Noda, Takehiro ;

Doki, Yuichiro ;

Eguchi, Hidetoshi .

ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (05) :868-876

[37] Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study) [J].

Streichart, Lillian ;

Felldin, Marie ;

Ekberg, Jana ;

Mjoernstedt, Lars ;

Lindner, Per ;

Lennerling, Annette ;

Brocker, Verena ;

Molne, Johan ;

Holgersson, Jan ;

Daenen, Kristien ;

Wennberg, Lars ;

Lorant, Tomas ;

Baid-Agrawal, Seema .

TRIALS, 2024, 25 (01)

[38] Unification of Treatments and Interventions for Tinnitus Patients (UNITI): a study protocol for a multi-center randomized clinical trial [J].

Schoisswohl, Stefan ;

Langguth, Berthold ;

Schecklmann, Martin ;

Bernal-Robledano, Alberto ;

Boecking, Benjamin ;

Cederroth, Christopher R. ;

Chalanouli, Dimitra ;

Cima, Rilana ;

Denys, Sam ;

Dettling-Papargyris, Juliane ;

Escalera-Balsera, Alba ;

Espinosa-Sanchez, Juan Manuel ;

Gallego-Martinez, Alvaro ;

Giannopoulou, Efi ;

Hidalgo-Lopez, Leyre ;

Hummel, Michael ;

Kikidis, Dimitris ;

Koller, Michael ;

Lopez-Escamez, Jose A. ;

Marcrum, Steven C. ;

Markatos, Nikolaos ;

Martin-Lagos, Juan ;

Martinez-Martinez, Maria ;

Martinez-Martinez, Marta ;

Ferron, Maria Mata ;

Mazurek, Birgit ;

Mueller-Locatelli, Nicolas ;

Neff, Patrick ;

Oppel, Kevin ;

Perez-Carpena, Patricia ;

Robles-Bolivar, Paula ;

Rose, Matthias ;

Schiele, Tabea ;

Schiller, Axel ;

Simoes, Jorge ;

Stark, Sabine ;

Staudinger, Susanne ;

Stege, Alexandra ;

Verhaert, Nicolas ;

Schlee, Winfried .

TRIALS, 2021, 22 (01)

[39] Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan [J].

Oki, Yasuhiro ;

Kondo, Yutaka ;

Yamamoto, Kazuhito ;

Ogura, Michinori ;

Kasai, Masanobu ;

Kobayashi, Yukio ;

Watanabe, Takashi ;

Uike, Naokuni ;

Ohyashiki, Kazuma ;

Okamoto, Shin-ichiro ;

Ohnishi, Kazunori ;

Tomita, Akihiro ;

Miyazaki, Yasushi ;

Tohyama, Kaoru ;

Mukai, Harumi Y. ;

Hotta, Tomomitsu ;

Tomonaga, Masao .

CANCER SCIENCE, 2012, 103 (10) :1839-1847

[40] Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis [J].

Mascarenhas, John O. ;

Talpaz, Moshe ;

Gupta, Vikas ;

Foltz, Lynda M. ;

Savona, Michael R. ;

Paquette, Ronald ;

Turner, A. Robert ;

Coughlin, Paul ;

Winton, Elliott ;

Burn, Timothy C. ;

O'Neill, Peter ;

Clark, Jason ;

Hunter, Deborah ;

Assad, Albert ;

Hoffman, Ronald ;

Verstovsek, Srdan .

HAEMATOLOGICA, 2017, 102 (02) :327-335

← 1 2 3 4 5 →